Evidence map›Paper›PMID 39809876›Full record

ArticleScientific reports2025

Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections.

Samuel Rischke, Robert Gurke, Ann-Sophie Zielbauer, Nicole Ziegler, Lisa Hahnefeld, Michaela Köhm, Aimo Kannt, Maria Jgt Vehreschild, Gerd Geisslinger, Gernot Rohde and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02139163 (Epidemiological Study on Community Acquired Pneumonia), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02139163 recruitingnot on this map

Epidemiological Study on Community Acquired Pneumonia

Typeobservational_patient_registrySponsorCapnetz StiftungRan2002 to 2028Enrolled20,000ConditionsCommunity Acquired Pneumonia
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Clinical lipidomics in bacterial sepsis: a systematic review of serum and plasma evaluations.Metabolomics : Official journal of the Metabolomic Society · 2026
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Samuel Rischke *Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Robert Gurke *Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt am Main, Germany. gurke@med.uni-frankfurt.de.
Ann-Sophie ZielbauerDepartment of Internal Medicine, Infectious Diseases, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Nicole ZieglerFraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Lisa HahnefeldInstitute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Michaela KöhmFraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Aimo KanntInstitute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Maria Jgt VehreschildFraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Gerd GeisslingerInstitute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Gernot RohdeDepartment of Respiratory Medicine, Medical Clinic I, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany.
Carla BellinghausenDepartment of Respiratory Medicine, Medical Clinic I, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany.
Frank BehrensFraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Capnetz Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Community-acquired pneumonia (CAP) has a significant impact on public health, especially in light of the recent SARS-CoV-2 pandemic. To enhance disease characterization and improve understanding of the underlying mechanisms, a comprehensive analysis of the plasma lipidome, metabolome and proteome was conducted in patients with viral and bacterial CAP infections, including those induced by SARS-CoV-2. Lipidomic, metabolomic and proteomic profiling were conducted on plasma samples of 69 patients suffering either from viral or bacterial CAP. Lipid and metabolite analyses were LC-MS-based, while proteomic analyses were performed using multiple panels of the Olink platform. Statistical methods, machine learning and pathway analyses were conducted investigating differences between the infection types. Through comparison of the bacterial and viral pathogen groups, distinct signatures were observed in the plasma profiles. Notably, linoleic acid-derived inflammation signaling metabolites (EpOME and DiHOME) were increased in viral CAP compared to bacterial CAP. Similarly, proteins involved in cellular immune response and apoptosis (LAG-3 and TRAIL) showed elevated levels in viral CAP, while bacterial CAP exhibited notable elevation in pattern-recognizing receptors (CLEC4D and EN-RAGE). Additionally, within the lipidomic profile at baseline, several lipids displayed notable differences between viral and bacterial pneumonia, including bile acids (GCA, TCA, TCDCA), various tri- and diglycerides (TGs and DGs), and several phosphatidylcholines (PCs). These findings hold promise for facilitating the differential diagnosis of viral and bacterial pulmonary infections based on the systemic lipidome, metabolome and proteome, enabling timely treatment decisions. Additionally, they highlight potential targets for drug research, advancing therapeutic interventions in CAP. By providing valuable insights into the molecular characterization of CAP, this study contributes to the improvement of understanding the disease and, ultimately, the development of effective treatment strategies.

Indexed as

Community-Acquired InfectionsCOVID-19LipidsMetabolomePneumonia, BacterialPneumonia, ViralAdultAgedCommunity-Acquired PneumoniaDiagnosis, DifferentialFemaleHumansLipidomicsMaleMetabolomicsMiddle AgedLipidsProteome

Identifiers

PMID39809876
PMCPMC11733231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.